Altimmune
Clinical-stage company whose main asset is pemvidutide, a GLP-1 and glucagon dual agonist for MASH and alcohol use disorder.
Share price
$2.61
Down 34% over 12 monthsWhat analysts expect
Buy
Buy80%
Hold10%
Sell10%
Price target for the next 12 months
$14.30Up 543% compared with the current price
Price now $2.23Average targetLowest $10.00 to highest $20.00
10 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $31K
- Yearly profit
- Loss $92M
- Company value
- $508M
Revenue and profit for the last twelve months reported.
Peptides in this book
- PemvidutideTrials only
Recent news
- 2026-08-03 Altimmune starts PERFORMA Phase 3 trial in MASH GlobeNewswire
- 2026-07-28 RECLAIM Phase 2 alcohol use disorder trial meets its primary endpoint GlobeNewswire
- 2026-08-12 Altimmune reports second quarter 2026 results and business update GlobeNewswire
Prices are delayed and figures rounded. Not investment advice.